GlassScriptPhysician profile
Timothy E Rowland
NPI 1629197314
$528.18
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $394 · 2020: $107 · 2024: $27.21.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $27.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $27.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $73.98 | 2019-2020 | |
| Novo Nordisk INC | $64.14 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $54.66 | 2019-2020 | |
| Amgen INC. | $41.47 | 2019-2020 | |
| Mylan Specialty L.P. | $37.31 | 2019-2020 | |
| Astellas Pharma US INC | $30.74 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.68 | 2019 | |
| Shire North American Group INC | $27.32 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.21 | 2024 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $26.30 | 2019 | |
| Pfizer INC. | $22.91 | 2019-2020 | |
| Genentech USA, INC. | $18.79 | 2019 | |
| Avanir Pharmaceuticals, INC. | $14.76 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.96 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.62 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $12.23 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.31 | 2019 | |
| Allergan, INC. | $10.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Rowland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.